Vanguard Group Inc Adagio Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.57 Trillion
Q4 2024

A detailed history of Vanguard Group Inc transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,339,863 shares of ADGI stock, worth $14.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,339,863

Previous 4,365,769 0.59%

Holding current value

$14.4 Million

Previous $14.5 Million 0.6%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	N/A	-25,906 Reduced 0.59%	4,339,863 $14.4 Million
Q3 2024 Nov 13, 2024	BUY	N/A	70,525 Added 1.64%	4,365,769 $14.5 Million
Q2 2024 Aug 13, 2024	BUY	N/A	1,684,042 Added 64.49%	4,295,244 $14.2 Million
Q1 2024 May 10, 2024	BUY	N/A	97,496 Added 3.88%	2,611,202 $8.64 Million
Q4 2023 Feb 14, 2024	BUY	N/A	24,692 Added 0.99%	2,513,706 $8.32 Million
Q2 2023 Aug 14, 2023	SELL	N/A	-210,968 Reduced 7.81%	2,489,014 $8.24 Million
Q1 2023 May 15, 2023	BUY	N/A	8,063 Added 0.3%	2,699,982 $8.94 Million
Q4 2022 Feb 10, 2023	SELL	$3.08 - $4.05 $3.47 Million - $4.57 Million	-1,127,994 Reduced 29.53%	2,691,919 $8.91 Million
Q3 2022 Nov 14, 2022	BUY	$2.97 - $4.83 $1.54 Million - $2.5 Million	517,645 Added 15.68%	3,819,913 $12 Million
Q2 2022 Aug 12, 2022	SELL	$2.54 - $4.52 $5.14 Million - $9.14 Million	-2,021,858 Reduced 37.98%	3,302,268 $10.8 Million
Q1 2022 May 13, 2022	BUY	$3.81 - $10.77 $14.4 Million - $40.8 Million	3,790,400 Added 247.14%	5,324,126 $24.3 Million
Q4 2021 Feb 14, 2022	SELL	$6.35 - $47.04 $2.4 Million - $17.8 Million	-377,899 Reduced 19.77%	1,533,726 $11.1 Million
Q3 2021 Nov 12, 2021	BUY	$20.88 - $56.08 $39.9 Million - $107 Million	1,911,625 New	1,911,625 $80.7 Million

Others Institutions Holding ADGI

# of Institutions

Shares Held

70.5M

Call Options Held

3.6K

Put Options Held

2.1K

View Full List

About Adagio Therapeutics, Inc.

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

More about ADGI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Adagio Therapeutics, Inc. Transaction History